Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nanologica ABOSTO:NICA +5.10%45 Current Ratio is 1.15 as of Mar. 2026, which is 65% below its 10-year median of 3.24. GuruFocus rates OSTO:NICA with a GF Score™ of 45/100 and a GF Value™ of kr4.24 (Possible Value Trap). The stock has 9 warning signs investors should review. Among 1,411 Biotechnology companies, Nanologica AB ranks worse than 81.64% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Nanologica AB's current ratio for the quarter that ended in Mar. 2026 was 1.15.
Nanologica AB has a current ratio of 1.15. It generally indicates good short-term financial strength.
The historical rank and industry rank for Nanologica AB's Current Ratio or its related term are showing as below:
OSTO:NICA'
s Current Ratio Range Over the Past 10 Years
Min: 0.54 Med: 3.24 Max: 8.77
Current: 1.15
During the past 12 years, Nanologica AB's highest Current Ratio was 8.77. The lowest was 0.54. And the median was 3.24.
OSTO:NICA's Current Ratio is ranked worse than 81.64% of 1411
companies
in the Biotechnology industry
Industry Median: 3.88
vs OSTO:NICA: 1.15
Nanologica AB (OSTO:NICA) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Nanologica AB Current Ratio Related Terms
Nanologica AB Current Ratio Historical Data
* Premium members only.
The historical data trend for Nanologica AB's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:NICA vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Nanologica AB's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanologica AB Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nanologica AB's Current Ratio distribution charts can be found below:
* The bar in red indicates where Nanologica AB's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanologica AB (OSTO:NICA) has a Current Ratio of 1.15 as of Mar. 2026. This is 65% below median its historical median of 3.24. Over the past decade, Nanologica AB's Current Ratio has ranged from 0.54 to 8.77. According to the industry distribution chart, Nanologica AB ranks #1152 out of 1411 companies in the Biotechnology industry, placing it in the top 81.6%.
Is Nanologica AB's Current Ratio too high?
Nanologica AB's current Current Ratio of 1.15 is 65% below median its 10-year median of 3.24. Over the past 10 years, this metric has ranged from a low of 0.54 to a high of 8.77. The Biotechnology industry median Current Ratio is 3.88. Nanologica AB's value of 1.15 is 70.4% below this industry median. Based on the distribution chart, Nanologica AB ranks #1152 out of 1411 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Nanologica AB has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nanologica AB's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nanologica AB ranks #1152 out of 1411 companies for Current Ratio. This places Nanologica AB in the lower half of its industry. The industry median Current Ratio is 3.88. Nanologica AB's value of 1.15 is 70.4% below this benchmark. Historically, Nanologica AB's own Current Ratio has ranged from 0.54 to 8.77 over the past decade. While the company's 10-year median is 3.24 vs. the industry median of 3.88, Nanologica AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.88, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanologica AB's current Current Ratio of 1.15 is 70.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanologica AB's current Current Ratio is 1.15, which is 65% below median its own 10-year median of 3.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanologica AB stock overvalued right now?
Based on GuruFocus' analysis, Nanologica AB (OSTO:NICA) is currently considered Possible Value Trap. The stock's GF Value™ is kr4.24, compared to a current price of kr0.47 — trading 88.8% below its estimated fair value. The current Current Ratio is 1.15, which is 65% below median its 10-year median of 3.24 and 70.4% below the Biotechnology industry median of 3.88. Nanologica AB's overall GF Score™ is 45/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Nanologica AB (OSTO:NICA), the current Current Ratio is 1.15 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanologica AB (OSTO:NICA) Overvalued in 2026?
Based on GuruFocus' analysis, Nanologica AB stock appears to be undervalued.
The current stock price of kr0.47 is trading 88.8% below its estimated GF Value™ of kr4.24.
GuruFocus considers Nanologica AB to be Possible Value Trap.
Key valuation signals for OSTO:NICA:
Current Ratio: 1.15 (65% below median its 10-year median of 3.24)
GF Value™: kr4.24 vs. price of kr0.47 (88.8% below fair value)
Industry Position: 70.4% below the Biotechnology median (#1152 of 1411)
No single metric tells the full story. See the OSTO:NICA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanologica AB is a Swedish life science tools company that develops, manufactures, and sells key consumables to pharmaceutical manufacturers. Its products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, it can increase productivity and reduce costs for pharmaceutical manufacturers. The group operates in a world-wide niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments.
45GF Score
Get the complete analysis for OSTO:NICA
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:NICA has been successfully added to your 
